Hikma expands Ohio site it got in Roxane deal, adding 95 workers

Hikma is expanding the large manufacturing site in Columbus, OH, it acquired in 2015 from Boehringer Ingelheim.

Jordan-based Hikma is expanding the manufacturing and distribution operations at a large solid-dose manufacturing site it picked up in 2015 from Boehringer Ingelheim, adding about 100 jobs in the process. 

HIkma’s West-Ward generics division has committed to adding 65 jobs as part of an expansion of the solid dose plant in Columbus, OH, in exchange for a 7-year tax credit worth up to $100,000 that was granted this week by the Ohio Tax Credit Authority, Columbus Business First reports.

Hikma got the 875,000-square-foot manufacturing site in Columbus with its $2.65 billion buyout in 2015 of Roxanne Laboratories, the U.S. generics business of Germany’s Boehringer Ingelheim. Hikma folded the new operation into its U.S.-based West-Ward, which produces both sterile injectables and solid dose products.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Work on a 30,300-square-foot, two-story expansion to the west Columbus plant began last summer, Business First says, and  is expected to open in phases through May 2018.

In addition, West-Ward is building a 276,000-square-foot distribution facility in nearby Obetz where it will add another 30 jobs.

Suggested Articles

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.